One Platform
Faster ECG Interpretation. Earlier Cardiac Insights.
Connect any ECG device. Deploy any algorithm. Integrate with any EHR. MyoVista Insights analyzes ECGs from any device to surface cardiac dysfunction that standard interpretation misses.
What is MyoVista Insights?
MyoVista Insights is an AI-powered ECG analysis platform that transforms standard 12-lead ECGs into actionable cardiac insights. Using advanced machine learning trained on millions of ECGs, it detects conditions often missed by traditional interpretation.
Multi-condition detection - Screens for 20+ cardiac conditions including left ventricular dysfunction and hypertrophic cardiomyopathy
Instant risk stratification - Prioritize patients who need immediate attention with confidence scores
Seamless EHR integration - Results flow directly into Epic, Cerner, MEDITECH, and other major systems
Enterprise-Ready Features
Built for healthcare organizations that demand reliability, security, and seamless integration
Vendor Neutral
Works with GE, Philips, Nihon Kohden, and any ECG device. No hardware lock-in, complete flexibility.
Cloud Native
Scalable AWS infrastructure with 99.9% uptime SLA. Auto-scaling to handle any volume.
AI Orchestration
Deploy multiple algorithms simultaneously. Mix and match AI models for comprehensive analysis.
EHR Integration
Native HL7 FHIR support. Pre-built connectors for Epic, Cerner, and all major EHR systems.
Real-time Processing
Results delivered in under 30 seconds. Immediate actionable insights for clinical workflows.
HIPAA Compliant
Enterprise-grade security with SOC 2 Type II certification. End-to-end encryption for all data.
The Challenge
Standard ECG interpretation cannot detect early-stage cardiac dysfunction, missing conditions that AI pattern recognition can identify.
- Diastolic dysfunction undetectable on standard ECGCirculation, 2022
- Low EF often missed until symptomaticEur Heart J, 2023
- Echo required for definitive diagnosisCost: $500-2,000 per study
HeartSciences Solution
Our algorithms detect cardiac dysfunction directly from ECG signals, identifying patients who need echocardiography before symptoms appear.
- 87% sensitivity for diastolic dysfunctionJACC: Heart Failure, 2024
- 91% sensitivity for low ejection fractionEur Heart J, 2023
- Works with any 12-lead ECG deviceVendor-neutral platform
What Clinicians Say
Healthcare professionals across the country trust HeartSciences for earlier detection and better patient outcomes.
"HeartSciences changed how we screen patients in primary care. The ability to detect diastolic dysfunction at the point of care has led to earlier referrals and better outcomes."
"The accuracy and consistency of the analysis has exceeded our expectations. We've integrated it into our standard cardiology workflow and it's become essential for triaging patients."
"As a cardiologist, I was initially skeptical. After using HeartSciences for six months, I can confidently say it catches things I would have missed on routine review."
Clinical Evidence
23+ peer-reviewed publications in Nature, JACC, and npj Digital Medicine
Estimate Your Savings
Based on 40% interpretation time reduction (Mount Sinai, 2024)
500
Hours saved per year
$37,500
Estimated annual savings
Estimates based on 15 min/ECG baseline, 40% time reduction (Mount Sinai, 2024), and 50 working weeks/year.
Actual results vary. Contact us for a personalized analysis.
Ready to Improve Your ECG Workflow?
See how HeartSciences can help your organization save time and improve cardiac detection.